Guardant Health, Inc. reported significant financial results for the third quarter of 2025, with total revenue reaching $265.2 million, a 39% increase from $191.5 million in the same period last year. For the nine months ending September 30, 2025, revenue totaled $700.8 million, up 30% from $537.2 million in 2024. The company attributed this growth primarily to increased oncology test volumes and the successful launch of its Shield blood test for colorectal cancer screening, which generated $24.1 million in revenue during the quarter.
Despite the revenue growth, Guardant Health incurred a net loss of $92.7 million for the third quarter, an improvement from the $107.8 million loss reported in the same quarter of 2024. For the nine-month period, the net loss was $287.8 million, compared to $325.4 million in the prior year. The company’s operating expenses also rose, totaling $364.2 million for the quarter, driven by increased costs in sales and marketing, research and development, and general administrative expenses.
Operationally, Guardant Health has seen a notable increase in its oncology test volume, which rose to approximately 74,000 tests in the third quarter of 2025, compared to about 53,100 tests in the same quarter of 2024. The company also reported a significant expansion in its customer base, with a growing number of biopharmaceutical partnerships contributing to its revenue. As of September 30, 2025, Guardant Health had cash, cash equivalents, and restricted cash totaling approximately $689.5 million, providing a solid liquidity position to support ongoing operations and strategic initiatives.
Looking ahead, Guardant Health plans to continue expanding its product offerings and geographic reach, particularly with its Shield platform, which has received FDA approval and Medicare coverage. The company is also focused on increasing its presence in international markets and enhancing its relationships with biopharmaceutical customers. However, it acknowledges the potential risks associated with reimbursement variability and market conditions that could impact future revenue growth. Guardant Health remains committed to investing in research and development to drive innovation and improve patient outcomes in precision oncology.
About Guardant Health, Inc.
Guardant Health, Inc. is a precision oncology company providing blood and tissue tests for cancer detection, monitoring, and therapy selection. Its core offerings include liquid biopsies, early detection screens, and companion diagnostics, serving patients, clinicians, and biopharmaceuticals globally. The company leverages advanced sequencing, AI, and real-world data to improve cancer outcomes and supports drug development and research through its comprehensive testing platform.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.